May 18, 2017
Bruce Trapnell, M.D., was frustrated. As a pulmonologist and professor of medicine and pediatrics at Cincinnati Children’s Hospital and University of Cincinnati Medical Centers, he suspected that an inhaled medication could help treat patients with autoimmune pulmonary alveolar proteinosis (aPAP), a rare, potentially deadly lung disease. But for several years, a series of financial and logistical obstacles stood in the way of proving his theory. Seeking collaborative support, Trapnell reached out to NCATS, which helped shepherd the potential therapy through several steps of the drug development process, ultimately enabling a clinical trial in aPAP patients.
See more information on this news item.